TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study for Identifying Optimal Simvastatin Formulation for Uniform Time to Maximum Plasma Concentration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* If the subject is female, she is eligible to enter and participate in this study if she is physiologically incapable of becoming pregnant or has a negative urine pregnancy test at screening and at baseline visit~* Negative Serology for Hepatitis B/C, HIV~* Non-OATP1B1\*5 carriers~* Negative Serology for anti-transglutaminase IgA antibody, and normal levels of total IgA~* For subjects with celiac disease, also~  * Diagnosis of celiac disease confirmed by medical history, histological evaluation of small intestinal mucosa on small bowel biopsy, and abnormal anti-transglutaminase antibody titers~ * Followed a gluten-free diet for at least one year, as verified by normal anti-transglutaminase antibody levels, Marsh 0-1 score on a follow-up biopsy within the past 12 months, and absence of any clinical signs or symptoms of celiac disease observed at diagnosis~Exclusion criteria:~* Current smoker or quit smoking less than 2 years ago~* Female breastfeeding or disagrees to use an effective mechanical contraceptive method (e.g. diaphragm or nonhormonal intrauterine device in combination with preservative)~* Presence of any known on-going disease which is judged to be relevant according to the investigator, besides celiac disease for the cohort of celiac patients in remission~* State after operations of the stomach or bowel (exception: appendectomy)~* Participation in any other clinical trial with investigational or approved drugs within the last month before the study~* Regular alcohol consumption of more than 25 g / day~* Use of any prescription or non-prescription drugs (including herbal supplements) must be discontinued 30 days prior to study (exceptions: paracetamol and NSAIDs, not taken longer than 2 days in a row and not taken within the last 3 days before the study)~* Consumption of grapefruit, star fruit, grapefruit juice, or star fruit juice must be discontinued 7 days prior to the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Liquid formulation of Simvastatin (Type: EXPERIMENTAL): None
- Tablet formulation of Simvastatin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Symptoms of Post-traumatic Stress in Adult Drug-resistant Epilepsies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Man or woman between 18 and 50 years old;~* Native French speaker;~* Level of education higher than the 3rd school level;~* Certain diagnosis of the pathology of the experimental group with which he will be associated, more precisely:~* Group of patients with epilepsy \[Group E\]: definite diagnosis of drug-resistant epilepsy (epileptic seizures persist despite the administration of daily treatment) established by a specialist physician.~* Group of patients with a heart rhythm disorder \[Group C\]: definite diagnosis of one of the following disorders: Atrial Fibrillation (AF); Syncope and Bouveret's disease established by a specialist.~* Group of patients with T1 diabetes mellitus \[Group D\]: definite diagnosis of type 1 diabetes established by a specialist doctor.~* Group of patients with PTSD \[Group T\]: definite diagnosis of PTSD established by a specialist doctor.~* Person having given his non-objection~Exclusion Criteria:~* Pregnancy;~* Breastfeeding women;~* Severe cognitive impairment~* Addiction to alcohol or drugs (including drugs other than those related to epilepsy or the chronic disease from which the patient has);~* Other neurological and / or psychiatric disorders than CNEP or epilepsy except anxiety and depressive disorders;~* Adults under guardianship or under judicial protection~* People deprived of their liberty~* Inability to read French.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Patients with epilepsy (Type: OTHER): None
- Patients with PTSD (Type: OTHER): None
- Patients with type 1 diabetes (Type: OTHER): None
- Patients with a heart rhythm disorder (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Neocartilage Implant to Treat Cartilage Lesions of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Generally, the following inclusion criteria must be met, however, this is not a complete list.~* Male or Female between the ages of 18 and 60~* (1) or (2) articular cartilage lesions of the distal femur ranging in no more than 5 cm2 each~* Ipsilateral knee compartment has intact menisci (or meniscectomized remnant with \> 5mm wide rim) and stable ligaments in the affected knee~* 3 months out from initiation of conservative non-surgical management (e.g.hyaluronic acid injection, activity modification) or previous minimal surgical intervention (e.g., arthroscopic lavage, debridement) or 12 months out from marrow stimulation for this condition~Exclusion Criteria:~Generally, if a potential participant meets any of the following criterions, they will not be eligible for this study. Additionally, more criteria will be evaluated to confirm eligibility as this list is not a complete list of criteria.~* Osteoarthritis~* Rheumatoid arthritis~* History of septic or reactive arthritis~* Gout or a history of gout or pseudo-gout in the affected knee~* Osteochondritis dissecans or osteochondral lesions of the knee with bone loss \> 6mm deep~* Bipolar articular cartilage involvement (or kissing lesions) of the ipsilateral compartment (i.e., \> than ICRS Grade 2 on the opposing articular surface)~* Associated damage to the underlying subchondral bone requiring an osteochondral graft~* Is pregnant or breast-feeding~* Has a BMI \> 35 (kg/m2)~* Has prior total meniscectomy of either knee~* Has received, within the past three months, intra-articular hyaluronic acid therapy, or steroid therapy~* Has more than two clinically relevant chondral lesion(s) on the index knee

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Neocartilage Implant (Type: ACTIVE_COMPARATOR): Neocartilage Implant surgically implanted and affixed to subchondral bone using commercial fibrin during mini-open knee arthrotomy.
- Microfracture (Type: OTHER): Standard of care cartilage repair technique.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: FURosemide Stress Test to Predict Need of Renal Replacement THERapy in Ischemic Acute Tubular Necrosis in ICU

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years old~* Hospitalized in ICU at day of inclusion~* Diagnosis of sepsis defined as proven or suspected infection and increase of the SOFA (Sequential Organ Failure Assessment) score by 2 points or more compared to basal OR Cardiothoracic surgery with CBP (Cardiopulmonary bypass) within 72 hours before inclusion~* Adequate cardiac output and volemia assessed by cardiac ultrasound, venous saturation in Oxygen (ScVO2) or ΔPP~* Hemodynamic stabilization : stable norepinephrine dosage (or \<20% variations) with no vascular filling during the last 3 hours~* AKI stage I or II in KDIGO classification~Exclusion Criteria:~* Chronic Kidney Disease with glomerular filtration rate ≤ 30 ml/mn/1,73m2~* Obstructive AKI~* AKI stage III in KDIGO classification~* Known allergy to loop diuretics~* Contraindications to Furosemide~* FST not feasible within 12 hours of eligibility~* Previous AKI during the same hospitalization~* Pregnancy or breastfeeding women~* Subject under a legal protective measure~* No affiliation to a social regime or CMU

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FST (Type: EXPERIMENTAL): FUROSEMIDE STRESS TEST

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: HO Prophylaxis Therapy for Distal Humerus Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient has a distal humerus fracture.~2. Patient's age is greater than or equal to 18~Exclusion Criteria:~1. Patient has a concomitant proximal ulna and/or proximal radius fracture~2. Patient requires external fixation of the elbow~3. Patient has quadriplegia or paraplegia~4. Patient requires intubation upon admission or for \>4 hours during admission for nonsurgical purposes~5. Patient has concomitant soft tissue damage in the affected elbow that cannot be appropriately closed within 72 hours of surgery~6. Patient has a burn affecting greater than or equal to 20% of the total body surface area or on the affected elbow~7. Patient has pre-existing heterotopic ossification in the affected elbow.~8. Patient is pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): This group will receive the standard of care treatment for their distal humerus fracture only.
- Intervention (Type: EXPERIMENTAL): This group will receive the prophylactic radiation therapy in addition to the standard of care treatment of their distal humerus fracture.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Single Arm Study Comparing ACC Supplement to CCS in Management of Hypoparathyroidism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary Hypoparathyroidism - low levels of intact PTH during hypocalcemia at diagnosis.~* Subjects receiving calcium and vitamin D supplementation at least 1 year prior to the beginning of the study.~* Subjects able to adhere to the visit schedule and protocol requirements and be available to complete the study.~* Subjects who provide written informed consent to participate in the study.~* Age: 18-80, inclusive.~Exclusion Criteria:~* Calcium (albumin corrected) serum values below 7.0 mg/dL or above 10.0 mg/dL~* Any known diseases affecting the absorption from the gastrointestinal tract:~  * Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)~ * Chronic diarrhea~* Subjects with neuropsychiatric disease.~* Subjects with impaired renal function (glomerular filtration rate, ≤40 mL/min)~* Subjects with other severe chronic disease requiring long-term therapy.~* Impaired liver function (Liver enzymes\> x3 upper limit of normal).~* Subjects with history or presence of kidney stones~* Recurrent urinary tract infections~* Subjects taking drugs which might affect calcium levels such as:~  * Fusid~ * Anticonvulsants~ * Carbonic anhydrase~ * Adrenocorticosteroids~* Subjects who are non-cooperative or unwilling to sign consent form.~* Pregnant or breast-feeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- amorphous calcium carbonate (Type: EXPERIMENTAL): Ten (10) subjects previously diagnosed and chronically treated for primary hypoparathyroidism will be enrolled. The daily CCS intake will be gradually replaced by reduced amount of elemental calcium from ACC. Five (5) subjects will consume the ACC before having a meal and the other five (5) subjects will consume the ACC after having a meal. The safety and the efficacy of the treatment will be closely monitored throughout this phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Cystic Fibrosis as documented by clinical features, and documentation of a positive sweat test or two disease causing mutation of the CF gene.~Exclusion Criteria:~* use of supplemental oxygen, FEV1 \< 40% predicted, inability to discontinue inhaled antibiotics for 4 weeks,~* hospitalization within 4 weeks prior to enrollment,~* change in maintenance CF therapies within 4 weeks of enrollment,~* severe anemia, significant chronic liver disease, severe pulmonary hypertension, prior organ transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sodium nitrite (Type: EXPERIMENTAL): Inhalation of 46 or 80 mg of sodium nitrite twice daily for four weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Double Blind Controlled Trial Comparing Sugammadex and Neostigmine After Thoracic Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects scheduled for pulmonary resection, lobectomy, pneumonectomy, bullectomy, pleurodesis~* Age 18-70 years~* American Society of Anesthesiologists (ASA) class 1, 2, 3~* Body mass Index (BMI) = 18-30 kg/m2~Exclusion Criteria:~* Subjects scheduled for esophagectomy, thoracectomy, vascular resection~* Chronic Obstructive Pulmonary Disease (COPD) Gold class III e IV, respiratory infection, asthma~* Preoperative Forced Expiratory Volume in 1 second (FEV1) \< 60% of predicted, Forced Expiratory Volume in 1 second/Forced Vital Capacity ratio (FEV1/FVC) \<70%~* Preoperative Diffusion Lung capacity for carbon monoxide/Alveolar Volume ratio (DLCO/VA) \< 60% of predicted~* Preoperative oxygen saturation (SpO2) \<92% or Partial pressure of oxygen in arterial blood/Fraction of inspired oxygen (PaO2/FiO2) ratio \<300~* Cardiovascular disease with Metabolic Equivalent of Tasks (METS) score less than 4~* Neuromuscular disorder~* Kidney failure defined as Estimated Glomerular Filtration Rate (eGFR) \< 30 ml/min/1,73 m2~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- S Group (Type: EXPERIMENTAL): Sugammadex 2 or 4 mg/kg iv once at the end of surgery
- N Group (Type: ACTIVE_COMPARATOR): Neostigmine 0.05 or 0.07 mg/kg (+ atropine 0.02 mg/kg) iv once at the end of surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Your child may be eligible for this trial if he/she:~* Had a kidney transplant 1 year ago or more;~* Is between 2 and 21 years of age (parent or guardian's signed informed consent required if under 18);~* Is taking stable, maintenance doses of immunosuppressive drugs for his/her kidney transplant; and~* Is generally in good health.~Exclusion Criteria:~Your child will not be eligible for this trial if he/she:~* Has had any rejection episodes in the last 6 months or has other problems with their kidneys;~* Was in the hospital for a major infection in the last 30 days;~* Has a history of VZV infection, including chicken pox or shingles;~* Has ever received a VZV vaccine, including Varivax®;~* Lives with a person whose immune system does not work well;~* Is allergic to certain medications;~* Is unable to return for the prescribed follow-up check-ups;~* Has no phone or pager; or~* Has had blood or plasma transfusions or taken certain drugs in the last 6 months.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Varivax® (Type: EXPERIMENTAL): 0.5 mL of Varivax administered subcutaneously in the right upper arm (deltoid region).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have undergone pancreaticoduodenectomy.~* Must have pancreatic remnant remaining in place (body and tail).~* Must be candidate for reconstruction by pancreaticojejunostomy by one of the two techniques described below.~* Must have an identifiable pancreatic duct which can be used for a duct-to-mucosa anastomosis.~Exclusion Criteria:~* Patients undergoing total pancreatectomy.~* Patients undergoing PD who have had previous left-sided pancreatic resection.~* Failure to sign informed consent.~* Failure to identify the pancreatic duct.~* Pregnant patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mucosa-to-jejunal mucosa technique of pancreaticojejunosto (Type: EXPERIMENTAL): Determine whether a duct mucosa-to-jejunal mucosa technique of pancreaticojejunostomy will improve the pancreatic fistula rate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically-confirmed diagnosis of invasive breast cancer~* Clinical stage T2, N0 or N1, M0 (TNM Classification)~* Patients must be postmenopausal~* Tumors are estrogen receptor (ER) positive and human epidermal growth factor receptor (HER2) negative~* ECOG Performance status (PS) 0 or 1~* Patients must be able to swallow tablets and capsules~* Candidates for mastectomy or breast-conserving surgery~* Adequate bone marrow, liver and renal function~* Written informed consent was obtained from all patients before randomization.~Exclusion Criteria:~* Inoperable, bilateral or inflammatory breast cancer~* multiple carcinoma~* Personal history of invasive carcinoma~* Patients receive systemic therapy of corticosteroid~* Patients receive estrogen preparation or raloxifene~* Patients with other concurrent severe and/or uncontrolled medical disease~* Patients whom doctors judged inadequate to the enrollment of this study by other reasons.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ANA (Type: ACTIVE_COMPARATOR): None
- ANA+UFT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: PEEP and V/Q Mismatch in Premature Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Preterm birth before 32 weeks gestational age by best obstetric estimate, determined by the clinical obstetric team during antepartum admission~2. Birth weight less than 1500 grams, as measured by the clinical team at neonatal admission.~3. Presence of endotracheal intubation and invasive mechanical ventilation~4. Less than or equal to 28 days chronologic age~5. Supplemental oxygen requirement, with a fraction of inspired oxygen (FiO2) equal to or greater than 0.25 as documented on the bedside infant flow sheet.~Exclusion Criteria:~1. Congenital anomalies, as determined by the clinical supervising physician~2. Current of prior air leak syndrome, as determined by the clinical supervising physician.~3. Non-English speaking parents~4. Non-viable birth, as determined by the clinical supervising physician

- Gender: ALL
- Minimum Age: 0 Days
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- Positive end-expiratory pressure (PEEP) level changes (Type: EXPERIMENTAL): Sequential changes in PEEP level within range of 4-8 cm H2O followed by measurement of V/Q mismatch at each level.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues